SCHEMBL376148

SCHEMBL376148

C[C@@H]1CN(C(=O)OC(C)(C)C)C[C@@H]1Nc1cncc(Cl)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.44
SSTR4 P31391 1/20 0.40
POLB P06746 1/20 0.38
BACE1 P56817 2/20 0.37
EHMT2 Q96KQ7 1/20 0.37
GPR119 Q8TDV5 1/20 0.36
ALDH1A1 P00352 2/20 0.36
PDE4B Q07343 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
STS P08842 1/20 0.35
NPC1 O15118 1/20 0.35
MAPT P10636 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MMP3 P08254 1/20 0.35
MMP7 P09237 1/20 0.35
MMP10 P09238 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22404953 0.87 EHMT2 (0.45) USP30SSTR4POLBEHMT2ALDH1A1
SCHEMBL1923473 0.84 CDK2 (0.35)
SCHEMBL20967210 0.82 USP30 (0.42) USP30POLBGPR119ALDH1A1STS
SCHEMBL376080 0.81 USP30 (0.48) USP30ALDH1A1NPC1MAPTMAPK1
SCHEMBL38665448 0.81 USP30 (0.48) USP30ALDH1A1NPC1MAPTMAPK1
SCHEMBL376081 0.81 USP30 (0.48) USP30ALDH1A1NPC1MAPTMAPK1
SCHEMBL3504310 0.81 ALDH1A1 (0.55) POLBEHMT2GPR119ALDH1A1STS
SCHEMBL376546 0.79 USP30 (0.46) USP30EHMT2ALDH1A1MEN1KMT2A
SCHEMBL376545 0.79 USP30 (0.46) USP30EHMT2ALDH1A1MEN1KMT2A
SCHEMBL31080376 0.77 POLB (0.37) USP30POLBGPR119MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2328890-B1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER (US) 2012-01-25 EP disclosed
EP-2328890-B1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER (US) 2012-01-25 EP disclosed
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC (US) 2011-06-16 US disclosed
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC (US) 2011-06-16 US disclosed
WO-2010016005-A1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS CHKA, CSNK1A1, CHKB USP30 3137/4885SSTR4 3061/4885POLB 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.